

DAFTAR PUSTAKA

- Alqahtani, A., Khan, Z., Alloghbi, A., Said Ahmed, T.S., Ashraf, M., Hammouda, D.M., 2019. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. *Med. Kaunas Lith.* 55, 526. <https://doi.org/10.3390/medicina55090526>
- Bousset, L., Gil, J., 2022. Targeting senescence as an anticancer therapy. *Mol. Oncol.* 16, 3855–3880. <https://doi.org/10.1002/1878-0261.13312>
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* 68, 394–424. <https://doi.org/10.3322/caac.21492>
- Cervello, M., Bachvarov, D., Lampiasi, N., Cusimano, A., Azzolina, A., McCubrey, J.A., Montalto, G., 2012. Molecular mechanisms of sorafenib action in liver cancer cells. *Cell Cycle* 11, 2843–2855. <https://doi.org/10.4161/cc.21193>
- Chang, Y.S., Adnane, J., Trail, P.A., Levy, J., Henderson, A., Xue, D., Bortolon, E., Ichetovkin, M., Chen, C., McNabola, A., Wilkie, D., Carter, C.A., Taylor, I.C.A., Lynch, M., Wilhelm, S., 2007. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor *apoptosis* and hypoxia in RCC xenograft models. *Cancer Chemother. Pharmacol.* 59, 561–574. <https://doi.org/10.1007/s00280-006-0393-4>
- Chaudhry, G.-S., Md Akim, A., Sung, Y.Y., Sifzizul, T.M.T., 2022. Cancer and *apoptosis*: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics. *Front. Pharmacol.* 13, 842376. <https://doi.org/10.3389/fphar.2022.842376>
- Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J.S., Luo, R., Feng, J., Ye, S., Yang, T.-S., Xu, J., Sun, Y., Liang, H., Liu, J., Wang, J., Tak, W.Y., Pan, H., Burock, K., Zou, J., Voliotis, D., Guan, Z., 2009. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol.* 10, 25–34. [https://doi.org/10.1016/S1470-2045\(08\)70285-7](https://doi.org/10.1016/S1470-2045(08)70285-7)
- Childs, B.G., Baker, D.J., Kirkland, J.L., Campisi, J., van Deursen, J.M., 2014. Senescence and *apoptosis*: dueling or complementary cell fates? *EMBO Rep.* 15, 1139–1153. <https://doi.org/10.15252/embr.201439245>
- Dauch, D., Rudalska, R., Cossa, G., Nault, J.-C., Kang, T.-W., Wuestefeld, T., Hohmeyer, A., Imbeaud, S., Yevsa, T., Hoenicke, L., Pantsar, T., Bozko, P., Malek, N.P., Longerich, T., Laufer, S., Poso, A., Zucman-Rossi, J., Eilers, M., Zender, L., 2016. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. *Nat. Med.* 22, 744–753. <https://doi.org/10.1038/nm.4107>
- Forner, A., Reig, M., Bruix, J., 2018. Hepatocellular carcinoma. *Lancet Lond. Engl.* 391, 1301–1314. [https://doi.org/10.1016/S0140-6736\(18\)30010-2](https://doi.org/10.1016/S0140-6736(18)30010-2)
- Galle, P.R., Foerster, F., Kudo, M., Chan, S.L., Llovet, J.M., Qin, S., Schelman, W.R., Chintharlapalli, S., Abada, P.B., Sherman, M., Zhu, A.X., 2019.

- Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. *Liver Int.* 39, 2214–2229. <https://doi.org/10.1111/liv.14223>
- Hasbiyani, N.A.F., Wulandari, F., Nugroho, E.P., Hermawan, A., Meiyanto, E., 2021. Bioinformatics Analysis Confirms the Target Protein Underlying Mitotic Catastrophe of 4T1 Cells under Combinatorial Treatment of PGV-1 and Galangin. *Sci. Pharm.* 89, 38. <https://doi.org/10.3390/scipharm89030038>
- Hasumura, S., Sujino, H., Nagamori, S., Kameda, H., 1988. [Establishment and characterization of a human hepatocellular carcinoma cell line JHH-4]. *Hum. Cell* 1, 98–100.
- Larasati, Y.A., Yoneda-Kato, N., Nakamae, I., Yokoyama, T., Meiyanto, E., Kato, J.-Y., 2018. Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. *Sci. Rep.* 8, 2039. <https://doi.org/10.1038/s41598-018-20179-6>
- Lee, M.S., Ryoo, Baek-Yeol, Hsu, Chih-Hung, Numata, Kazushi, Stein, Stacey, Verret, W., Hack, S.P., Spahn, J., Liu, B., Abdullah, H., Wang, Y., He, Aiwu Ruth, Lee, K.-H., Bang, Y.-J., Bendell, J., Chao, Y., Chen, J.-S., Chung, H.C., Davis, S.L., Dev, A., Gane, E., George, B., He, A R, Hochster, H., Hsu, C-H, Ikeda, M., Lee, J., Lee, M., Mahipal, A., Manji, G., Morimoto, M., Numata, K, Pishvaian, M., Qin, S., Ryan, D., Ryoo, B-Y, Sasahira, N., Stein, S, Strickler, J., Tebbutt, N., 2020. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. *Lancet Oncol.* 21, 808–820. [https://doi.org/10.1016/S1470-2045\(20\)30156-X](https://doi.org/10.1016/S1470-2045(20)30156-X)
- Lestari, B., Nakamae, I., Yoneda-Kato, N., Morimoto, T., Kanaya, S., Yokoyama, T., Shionyu, M., Shirai, T., Meiyanto, E., Kato, J., 2019. Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence. *Sci. Rep.* 9, 14867. <https://doi.org/10.1038/s41598-019-51244-3>
- Llovet, J.M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., Gores, G., 2016. Hepatocellular carcinoma. *Nat. Rev. Dis. Primer* 2, 16018. <https://doi.org/10.1038/nrdp.2016.18>
- Marin, J.J.G., Macias, R.I.R., Monte, M.J., Romero, M.R., Asensio, M., Sanchez-Martin, A., Cives-Losada, C., Temprano, A.G., Espinosa-Escudero, R., Reviejo, M., Bohorquez, L.H., Briz, O., 2020. Molecular Bases of Drug Resistance in Hepatocellular Carcinoma. *Cancers* 12, 1663. <https://doi.org/10.3390/cancers12061663>
- Matsuzawa, N., Takamura, T., Kurita, S., Misu, H., Ota, T., Ando, H., Yokoyama, M., Honda, M., Zen, Y., Nakanuma, Y., Miyamoto, K.-I., Kaneko, S., 2007. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. *Hepatology* 46, 1392–1403. <https://doi.org/10.1002/hep.21874>
- Meiyanto, E., Husnaa, U., Kastian, R.F., Putri, H., Larasati, Y.A., Khumaira, A., Pamungkas, D.D.P., Jenie, R.I., Kawaichi, M., Lestari, B., Yokoyama, T., Kato, J., 2020. The Target Differences of Anti-Tumorigenesis Potential of Curcumin and its Analogues Against HER-2 Positive and Triple-Negative

- Breast Cancer Cells. *Adv. Pharm. Bull.* 11, 188–196.
<https://doi.org/10.34172/apb.2021.020>
- Meiyanto, E., Putri, D.D.P., Susidarti, R.A., Murwanti, R., Sardjiman, S., Fitriasari, A., Husnaa, U., Purnomo, H., Kawaichi, M., 2014. Curcumin and its Analogues (PGV-0 and PGV-1) Enhance Sensitivity of Resistant MCF-7 Cells to Doxorubicin through Inhibition of HER2 and NF-κB Activation. *Asian Pac. J. Cancer Prev.* 15, 179–184.
<https://doi.org/10.7314/APJCP.2014.15.1.179>
- Moordiani, M., Novitasari, D., Susidarti, R.A., Ikawati, M., Kato, J., Meiyanto, E., 2023. Curcumin Analogs PGV-1 and CCA-1.1 Induce Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells with Overexpressed MYCN. *Indones. Biomed. J.* 15, 141–9. <https://doi.org/10.18585/inabj.v15i2.2147>
- Novitasari, D., Kato, J., Ikawati, M., Putri, D.D.P., Wulandari, F., Widyarini, S., Zulfin, U.M., Salsabila, D.U., Meiyanto, E., 2023. PGV-1 permanently arrests HepG2 cells in M phase and inhibits liver carcinogenesis in DMH-induced rats. *J. Appl. Pharm. Sci.*
<https://doi.org/10.7324/JAPS.2023.131550>
- Novitasari, D., Nakamae, I., Istighfari Jenie, R., Yoneda-Kato, N., Kato, J., Meiyanto, E., 2024. Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies. *Saudi Pharm. J.* 32, 101892.
<https://doi.org/10.1016/j.jsps.2023.101892>
- Pfeffer, C.M., Singh, A.T.K., 2018. *Apoptosis*: A Target for Anticancer Therapy. *Int. J. Mol. Sci.* 19, 448. <https://doi.org/10.3390/ijms19020448>
- Qin, X.-Y., Gailhouse, L., 2021. Non-Genomic Control of Dynamic MYCN Gene Expression in Liver Cancer. *Front. Oncol.* 10, 618515.
<https://doi.org/10.3389/fonc.2020.618515>
- Qin, X.-Y., Hara, M., Arner, E., Kawaguchi, Y., Inoue, I., Tatsukawa, H., Furutani, Y., Nagatsuma, K., Matsuura, T., Wei, F., Kikuchi, J., Sone, H., Daub, C., Kawaji, H., Lassmann, T., Itoh, M., Suzuki, H., Carninci, P., Hayashizaki, Y., FANTOM consortium, Kokudo, N., Forrest, A.R.R., Kojima, S., 2017. Transcriptome Analysis Uncovers a Growth-Promoting Activity of Orosomucoid-1 on Hepatocytes. *EBioMedicine* 24, 257–266.
<https://doi.org/10.1016/j.ebiom.2017.09.008>
- Qin, X.-Y., Suzuki, H., Honda, M., Okada, H., Kaneko, S., Inoue, I., Ebisui, E., Hashimoto, K., Carninci, P., Kanki, K., Tatsukawa, H., Ishibashi, N., Masaki, T., Matsuura, T., Kagechika, H., Toriguchi, K., Hatano, E., Shirakami, Y., Shiota, G., Shimizu, M., Moriwaki, H., Kojima, S., 2018. Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid. *Proc. Natl. Acad. Sci.* 115, 4969–4974. <https://doi.org/10.1073/pnas.1802279115>
- Rahmawati, D.R., Nurrochmad, A., Jenie, R.I., Meiyanto, E., 2023. The Synergistic Cytotoxic Effect of Pentagamavunon-1 (PGV-1) and Curcumin Correlates with the Cell Cycle Arrest to Induce Mitotic Catastrophe in 4T1 and T47D Breast Cancer Cells. *Indones. Biomed. J.* 15, 318–27.
<https://doi.org/10.18585/inabj.v15i5.2594>

- Roger, L., Tomas, F., Gire, V., 2021. Mechanisms and Regulation of Cellular Senescence. *Int. J. Mol. Sci.* 22, 13173. <https://doi.org/10.3390/ijms222313173>
- Sim, H.-W., Knox, J., 2018. Hepatocellular carcinoma in the era of immunotherapy. *Curr. Probl. Cancer* 42, 40–48. <https://doi.org/10.1016/j.crrproblcancer.2017.10.007>
- Suenaga, Y., Islam, S.M.R., Alagu, J., Kaneko, Y., Kato, M., Tanaka, Y., Kawana, H., Hossain, S., Matsumoto, D., Yamamoto, M., Shoji, W., Itami, M., Shibata, T., Nakamura, Y., Ohira, M., Haraguchi, S., Takatori, A., Nakagawara, A., 2014. NCYM, a Cis-Antisense Gene of MYCN, Encodes a De Novo Evolved Protein That Inhibits GSK3 β Resulting in the Stabilization of MYCN in Human Neuroblastomas. *PLoS Genet.* 10, e1003996. <https://doi.org/10.1371/journal.pgen.1003996>
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S., 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131, 861–872. <https://doi.org/10.1016/j.cell.2007.11.019>
- Tang, W., Chen, Z., Zhang, W., Cheng, Y., Zhang, B., Wu, F., Wang, Q., Wang, S., Rong, D., Reiter, F.P., De Toni, E.N., Wang, X., 2020. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. *Signal Transduct. Target. Ther.* 5, 87. <https://doi.org/10.1038/s41392-020-0187-x>
- Wilhelm, S.M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., Cao, Y., Shujath, J., Gawlak, S., Eveleigh, D., Rowley, B., Liu, L., Adnane, L., Lynch, M., Auclair, D., Taylor, I., Gedrich, R., Voznesensky, A., Riedl, B., Post, L.E., Bollag, G., Trail, P.A., 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res.* 64, 7099–7109. <https://doi.org/10.1158/0008-5472.CAN-04-1443>
- Zeng, H., Zheng, R., Guo, Y., Zhang, S., Zou, X., Wang, N., Zhang, L., Tang, J., Chen, Jianguo, Wei, K., Huang, S., Wang, J., Yu, L., Zhao, D., Song, G., Chen, Jianshun, Shen, Y., Yang, X., Gu, X., Jin, F., Li, Q., Li, Y., Ge, H., Zhu, F., Dong, J., Guo, G., Wu, M., Du, L., Sun, X., He, Y., Coleman, M.P., Baade, P., Chen, W., Yu, X.Q., 2015. Cancer survival in China, 2003–2005: A population-based study. *Int. J. Cancer* 136, 1921–1930. <https://doi.org/10.1002/ijc.29227>
- Zhang, H., Zhang, W., Jiang, L., Chen, Y., 2022. Recent advances in systemic therapy for hepatocellular carcinoma. *Biomark. Res.* 10, 3. <https://doi.org/10.1186/s40364-021-00350-4>